James Brockbank1, Sorrel Wolowacz2. 1. RTI Health Solutions, The Pavilion, Towers Business Park, Wilmslow Road, Didsbury, Manchester, M202LS, UK. jbrockbank@rti.org. 2. RTI Health Solutions, The Pavilion, Towers Business Park, Wilmslow Road, Didsbury, Manchester, M202LS, UK.
Abstract
BACKGROUND: Total hip replacement (THR) and total knee replacement (TKR) surgeries are being performed with increasing regularity and are associated with a high risk of developing a venous thromboembolism (VTE). New oral anticoagulants (NOACs) may be more effective at preventing VTEs but are associated with more bleeding events versus traditional anticoagulants. OBJECTIVE: The objective of this systematic review was to identify published economic analyses of NOACs for primary VTE prophylaxis following THR and TKR surgeries, and to summarise the modelling techniques used and the cost-effectiveness results. METHODS: Electronic searches of MEDLINE, EconLit and The Cochrane Library were performed from January 2008 to February 2015. Reference lists of included articles and reviews were examined for relevant studies. RESULTS: Sixteen relevant economic analyses were identified, all of which used decision-tree structures to model acute events after surgery; 13 included a chronic-phase Markov module to capture long-term complications of VTE and recurrent VTE events. All studies included prophylaxis-related major bleeding events and captured both symptomatic and asymptomatic VTE-related events; nine studies distinguished between distal and proximal deep vein thrombosis events. Overall, rivaroxaban dominated enoxaparin in eight of 11 studies and dalteparin in one study, dabigatran dominated enoxaparin in five of seven studies and apixaban dominated enoxaparin in two of two studies. Rivaroxaban dominated dabigatran in four of four studies, apixaban dominated dabigatran in two of two studies and rivaroxaban dominated apixaban in one study. CONCLUSIONS: The economic analyses showed reasonable consistency in the model structures used and the events captured. The results strongly suggested that NOACs are cost effective alternatives to low molecular-weight heparin. Dabigatran appeared to be the least cost effective NOAC. More research is needed to assess the cost effectiveness of apixaban and edoxaban.
BACKGROUND: Total hip replacement (THR) and total knee replacement (TKR) surgeries are being performed with increasing regularity and are associated with a high risk of developing a venous thromboembolism (VTE). New oral anticoagulants (NOACs) may be more effective at preventing VTEs but are associated with more bleeding events versus traditional anticoagulants. OBJECTIVE: The objective of this systematic review was to identify published economic analyses of NOACs for primary VTE prophylaxis following THR and TKR surgeries, and to summarise the modelling techniques used and the cost-effectiveness results. METHODS: Electronic searches of MEDLINE, EconLit and The Cochrane Library were performed from January 2008 to February 2015. Reference lists of included articles and reviews were examined for relevant studies. RESULTS: Sixteen relevant economic analyses were identified, all of which used decision-tree structures to model acute events after surgery; 13 included a chronic-phase Markov module to capture long-term complications of VTE and recurrent VTE events. All studies included prophylaxis-related major bleeding events and captured both symptomatic and asymptomatic VTE-related events; nine studies distinguished between distal and proximal deep vein thrombosis events. Overall, rivaroxaban dominated enoxaparin in eight of 11 studies and dalteparin in one study, dabigatran dominated enoxaparin in five of seven studies and apixaban dominated enoxaparin in two of two studies. Rivaroxaban dominated dabigatran in four of four studies, apixaban dominated dabigatran in two of two studies and rivaroxaban dominated apixaban in one study. CONCLUSIONS: The economic analyses showed reasonable consistency in the model structures used and the events captured. The results strongly suggested that NOACs are cost effective alternatives to low molecular-weight heparin. Dabigatran appeared to be the least cost effective NOAC. More research is needed to assess the cost effectiveness of apixaban and edoxaban.
Authors: Michael Rud Lassen; Alexander Gallus; Gary E Raskob; Graham Pineo; Dalei Chen; Luz Margarita Ramirez Journal: N Engl J Med Date: 2010-12-23 Impact factor: 91.245
Authors: S E Wolowacz; N S Roskell; J M Plumb; A Clemens; H Noack; P A Robinson; G Dolan; I J Brenkel Journal: Thromb Haemost Date: 2009-12-18 Impact factor: 5.249
Authors: Michael Rud Lassen; Gary E Raskob; Alexander Gallus; Graham Pineo; Dalei Chen; Philip Hornick Journal: Lancet Date: 2010-03-06 Impact factor: 79.321
Authors: J F Gómez-Cerezo; I Gómez-Arrayás; C Suárez-Fernández; L Betegón-Nicolás; M de Salas-Cansado; C Rubio-Terrés Journal: Rev Esp Cir Ortop Traumatol Date: 2012-09-07
Authors: Michael Rud Lassen; Gary E Raskob; Alexander Gallus; Graham Pineo; Dalei Chen; Ronald J Portman Journal: N Engl J Med Date: 2009-08-06 Impact factor: 91.245
Authors: Dalia M Dawoud; David Wonderling; Jessica Glen; Sedina Lewis; Xavier L Griffin; Beverley J Hunt; Gerard Stansby; Michael Reed; Nigel Rossiter; Jagjot Kaur Chahal; Carlos Sharpin; Peter Barry Journal: Front Pharmacol Date: 2018-11-27 Impact factor: 5.810
Authors: Lidia García-Pérez; Vanesa Ramos-García; Pedro Serrano-Aguilar; José Luis Pais-Brito; María Aciego de Mendoza; Jesús Martín-Fernández; Roberto García-Maroto; Juan Carlos Arenaza; Amaia Bilbao Journal: Health Qual Life Outcomes Date: 2019-10-30 Impact factor: 3.186
Authors: Mark G Pritchard; Jacqueline Murphy; Lok Cheng; Roshni Janarthanan; Andrew Judge; Jose Leal Journal: BMJ Open Date: 2020-01-15 Impact factor: 2.692